# (19) World Intellectual Property Organization International Bureau



# 

(43) International Publication Date 1 July 2004 (01.07.2004)

**PCT** 

(10) International Publication Number WO 2004/054581 A2

- (51) International Patent Classification<sup>7</sup>: A61K 31/46, 31/438, A61P 31/18, 31/04, C07D 451/02, 471/10, 333/52, 211/26, 401/04
- (21) International Application Number:

PCT/US2003/039732

(22) International Filing Date:

12 December 2003 (12.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/433,552

13 December 2002 (13.12.2002) US

- (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19101 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DUAN, Maosheng [CN/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). KAZMIERSKI, Wieslaw, Mieczyslaw [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). AQUINO, Christopher,

Joseph [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).


- (74) Agents: LEVY, David, J et al.; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS



(57) Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

WO 2004/054581 A2 ||||||

# (19) World Intellectual Property Organization International Bureau



(43) International Publication Date 1 July 2004 (01.07.2004)

**PCT** 

(10) International Publication Number WO 2004/054581 A3

- (51) International Patent Classification<sup>7</sup>: A61K 31/46, 31/438, A61P 31/18, 31/04, C07D 451/02, 471/10, 333/52, 211/26, 401/04 // (C07D 471/10, 235:00, 221:00) (C07D 471/10, 221:00, 209:00)
- (21) International Application Number:

PCT/US2003/039732

(22) International Filing Date:

12 December 2003 (12.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/433,552

13 December 2002 (13.12.2002) US

(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19101 (US).

(72) Inventors; and

[CN/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). KAZMIERSKI, Wieslaw, Mieczyslaw [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). AQUINO, Christopher, Joseph [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).


- (74) Agents: LEVY, David, J. et al.; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:
  3 February 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS



(57) Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

PC1/ US U3/39732

Relevant to daim No.

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/46 A61K31/438 A61P31/18 A61P31/04 C07D451/02 C07D471/10 C07D333/52 C07D211/26 C07D401/04 //(C07D471/10,235:00,221:00),(C07D471/10,221:00,209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

Category °

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K A61P C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

Citation of document, with indication, where appropriate, of the relevant passages

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data, BIOSIS, EMBASE

X	EP 1 182 195 A (TAKEDA CHEMICAL LTD) 27 February 2002 (2002-02-2 page 130, line 49 - line 51; cleans reamples 70,73	27)	1-21, 23-36
X	WO 01/72751 A (MUNSCHAUER RAINE (DE); RAFFERTY PAUL (GB); JOHNS N) 4 October 2001 (2001-10-04) claim 1; examples 197,196	· ·	1-21, 23-39
E	EP 1 403 255 A (SUMITOMO PHARMA 31 March 2004 (2004-03-31) claims; example 159	)	1-21, 23-39
X	US 6 479 487 B1 (BORCHERDING DA AL) 12 November 2002 (2002-11-1 column 138, paragraph 5; claims 29,18; table 1	2)	1-21, 23-39
		-/	
X Fu	ther documents are listed in the continuation of box C.	X Patent family members are listed	in annex.
"A" docum cons "E" earlier filing "L" docum whic citati "O" docum other	nent defining the general state of the art which is not idered to be of particular relevance redocument but published on or after the international date nent which may throw doubts on priority claim(s) or his cited to establish the publication date of another on or other special reason (as specified) ment referring to an oral disclosure, use, exhibition or remeans nent published prior to the international filing date but than the priority date claimed	<ul> <li>"T" later document published after the interpriority date and not in conflict with cited to understand the principle or the invention</li> <li>"X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the decument of particular relevance; the cannot be considered to involve an indocument is combined with one or ments, such combination being obvious in the art.</li> <li>"&amp;" document member of the same patent</li> </ul>	claimed invention of the considered to ocument is taken alone claimed invention ocument is taken alone claimed invention oventive step when the lore other such docu-
	e actual completion of the international search  9 November 2004	Date of mailing of the international se	
Name and	i mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL – 2280 HV Rijswijk  Tel. (+31–70) 340–2040, Tx. 31 651 epo nl,  Fax: (+31–70) 340–3016	Authorized officer Härtinger, S	

Inten | Application No PCi/US 03/39732

		101/03 03/39/32
C.(Continu Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/49018 A (NOVARTIS ERFINDUNGEN; CARAVATTI GIORGIO (CH); NOVARTIS AG (CH); IMBAC) 24 August 2000 (2000-08-24) claims; examples 6-9	1-21, 23-39
<b>X</b>	WOLTERSDORF O W ET AL: "Topically Active Anhydrase Inhibitors. 1. 0-Acyl Derivatives of 6-Hydroxybenzothiazole-2-sulfonamide" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 32, no. 11, 1989, pages 2486-2492, XP002282653 ISSN: 0022-2623 example 28; table 1	1,4-7, 27,28, 33,34
X	WO 97/20823 A (CRISCIONE LEOLUCA; YAMAGUCHI YASUCHIKA (CH); CIBA GEIGY AG (CH); MAH) 12 June 1997 (1997-06-12) claims 1-8; examples	1,4-7, 27,28, 33,34
X	DE 44 17 163 A (HOECHST SCHERING AGREVO GMBH) 23 November 1995 (1995-11-23) claims 1-8; tables	1,4-7
X	WO 99/59974 A (VONG ANTONIO KUOK KEONG; SMITHKLINE BEECHAM PLC (GB)) 25 November 1999 (1999-11-25) claims 1-6; examples	1,4-7, 27,28, 33,34
X	WO 99/64044 A (ADVANCED MEDICINE INC; CHOI SEOK KI (US); GRIFFIN JOHN H (US); MARQUE) 16 December 1999 (1999-12-16) page 114; claims 1-29; example 149	1,4-7, 27,28, 33,34
X	WO 97/09308 A (LILLY CO ELI) 13 March 1997 (1997-03-13) claims 1-11; example 273	1,4-7, 27,28, 33,34
P,X	WO 03/087098 A (DAVIES DAVID THOMAS; MARKWELL ROGER EDWARD (GB); BROOKS GERALD (GB);) 23 October 2003 (2003-10-23)	1,4-7, 25,27, 28,31, 33,34
Ρ,Χ	Claims 1-11; examples  WO 03/068237 A (BLASKOVICH MARK A; KIM HWA-OK (US); OGBU CYPRIAN O (US); MOLECUMETICS) 21 August 2003 (2003-08-21) claims 1-19; example 120; tables 3,4	1,4-7, 27,28, 34-36
P,X	WO 03/070244 A (ABBOTT LAB) 28 August 2003 (2003-08-28)  page 40 - page 44; claims 1-36	1,4-7, 27,28, 33,34

Interna Application No PCT/ US 03/39732

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Ρ,Χ	WO 03/075853 A (SQUIBB BRISTOL MYERS CO; CHERNEY ROBERT J (US)) 18 September 2003 (2003-09-18) claim 26; example 122	1,4-7, 23-39
P,X	WO 03/028641 A (OMODERA KATSUNORI; SEKIGUCHI YOSHINORI (JP); KANUMA KOSUKE (JP); TAIS) 10 April 2003 (2003-04-10) claims 1,13; examples	1,4-7, 27,28, 33,34
X	WITHERINGTON ET AL: "Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 11, no. 16, 2001, pages 2177-2180, XP002208447 ISSN: 0960-894X	1-6, 12-15, 17, 19-21, 23-39
Α	table 5; compound 8	7-11,16, 18,22
E	EP 1 378 510 A (ONO PHARMACEUTICAL CO) 7 January 2004 (2004-01-07)	1-7,11, 16, 19-21, 23-39
X	page 17, line 38; claim 1; example 8 & WO 02/074770 A (ONO PHARMACEUTICAL CO; TAKAOKA YOSHIKAZU (JP); SHIBAYAMA SHIRO (JP);) 26 September 2002 (2002-09-26)	1-7,11, 16, 19-21, 23-39
A	WO 01/90106 A (PRICE DAVID ANTHONY; PFIZER LTD (GB); WOOD ANTHONY (GB); PERROS MANOU) 29 November 2001 (2001-11-29) example 4	1-39
A	WO 02/18335 A (MORIHIRA KOICHIRO; MOROKATA TATSUAKI (JP); TAKAHASHI TOSHIYA (JP); YO) 7 March 2002 (2002-03-07) claim 1; examples 381,382	1-39
A	EP 1 236 726 A (ONO PHARMACEUTICAL CO) 4 September 2002 (2002-09-04) page 11, line 23 - line 43; claim 9; examples 20,24,67; tables 14b,32	1-32
X	WO 98/25897 A (PATCHETT ARTHUR A ; CHEN MENG H (US); WU MU TSU (US); YANG LIHU (US);) 18 June 1998 (1998-06-18)	1-6, 23-39
A	claims; example 10	7–22
X	WO 01/36418 A (PETTERSSON INGRID; HOHLWEG ROLF (DK); NOVO NORDISK AS (DK); WATSON BR) 25 May 2001 (2001-05-25)	1-6
Α	claims; example 4	7-22

tional application No. PCT/US 03/39732

# INTERNATIONAL SEARCH REPORT

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sneet)
This Inte	mational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: 1-21,23-27,33-39 because they relate to subject matter not required to be searched by this Authority, namely:
2. X	Although claims 23-27 and claims 37-39 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compound, however, only to the extent to which the compound could be searched.
з	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Int	ernational Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
з. 🗶	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  1-39(part)
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Rema	The additional search fees were accompanied by the applicant's protest.   No protest accompanied the payment of additional search fees.

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 23-27 and claims 37-39 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compound, however, only to the extent to which the compound could be searched.

Continuation of Box I.2

Claims Nos.: 1-21,33-36

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. As the formula I basically amounts define a nitrogen containing group (cf. R1) substituted cyclohexyl ring, which is bound via a linker of one to 5 elements selected from carbon, nitrogen, oxygen, sulfur or phosphorus (cf. X) to a further nitrogen containing ring (cf. ring A), the substructure search in the STN Registry database resulted in more than 3400 compounds even for a refined search, which takes into consideration the further definitions in claim 1. So many documents were retrieved relating to the said compound hits, some of them also relate to the claimed antiviral and antibacterial use, that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claims is impossible. Consequently, the search has been restricted to the use of the said compounds in the reatment of viral or bacterial infections (cf. claims 23 and 25).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

### IN I EKNA I IUNAL SEAKUN KEPUK I

linermation on patent family members

Interna d Application No PCT/US 03/39732

				101/03	03/39/32
Patent document cited in search repor	t	Publication date		Patent family member(s)	Publication date
EP 1182195	Α	27-02-2002	AU CA EP US	4145200 A 2373073 A1 1182195 A1 6627651 B1	21-11-2000 16-11-2000 27-02-2002 30-09-2003
			WO JP	0068203 A1 2001026586 A	16-11-2000 30-01-2001
WO 0172751	A	04-10-2001	WO AU	0172751 A1 4057000 A	04-10-2001 08-10-2001
EP 1403255	Α	31-03-2004	EP US	1403255 A1 2004138286 A1	31-03-2004 15-07-2004
			WO	02100833 A1	19-12-2002
US 6479487	B1	12-11-2002	AP AU	1054 A 747151 B2	01-04-2002 09-05-2002
			AU	2770999 A	15-09-1999
			BR	9909256 A	28-11-2000
			CA	2320474 A1	02-09-1999
			CN	1143858 C	31-03-2004
			EE	200000489 A	15-04-2002
				1056744 A1	06-12-2000
			EP	0100889 A2	28-01-2002
			HU	2002504552 T	12-02-2002
			JP NO		25-10-2000
			NO DI	20004280 A	
			PL	342604 A1	18-06-2001
			SK	12902000 A3	09-04-2001
			TR	200002463 T2	21-12-2000
			WO	9943675 A1	02-09-1999
			US	2003105098 A1	05-06-2003
			ZA	9901551 A	26-08-1999
			AT	252583 T	15-11-2003
			DE	69912248 D1	27-11-2003
			DE	69912248 T2	22-04-2004
			DK	1056744 T3	23-02-2004
			ES	2207182 T3	16-05-2004
			HK	1030949 A1	19-03-2004
			ID	25444 A	05-10-2000
			NZ	506235 A	28-02-2003
			OA	11455 A	05-12-2003
			PT	1056744 T	31-03-2004
			RU	2200162 C2	10-03-2003 29-02-2004
			SI 	1056744 T1 	
WO 0049018	Α	24-08-2000	AT	265456 T	15-05-2004
			AU	3804500 A	04-09-2000
			BR	0008365 A	13-11-2001
			CA	2360353 A1	24-08-2000
			CN	1340054 T	13-03-2002
			DE	60010234 D1	03-06-2004
			WO	0049018 A1	24-08-2000
			EP	1153024 A1	14-11-2001
			JP	2002537300 T	05-11-2002
				1153024 T	31-08-2004
			PT	1122054	01 00 2007
			US	2002016329 A1	07-02-2002
WO 9720823	A	 12-06-1997			

### IN LEKINA LIUNAL SEARUN REFURI

Inter al Application No PC 1/US 03/39732

					PC1/U3	03/39/32
=	tent document in search report		Publication date		Patent family member(s)	Publication date
WO	9720823	Α		ZA	9610020 A	01-06-1997
DE	4417163	A	23-11-1995	DE AU AU	4417163 A1 703538 B2 2523595 A	23-11-1995 25-03-1999 05-12-1995
				BR	9507647 A	09-09-1997
				CA CN	2190495 A1 1148383 A	23-11-1995 23-04-1997
				WO	9531441 A1	23-11-1995
				EP	0759909 A1	05-03-1997
				HU	76722 A2	28-10-1997
				JP	10500115 T	06-01-1998
				TR	28488 A	12-08-1996 25-11-1997
				US ZA	5691321 A 9503957 A	19-01-1996
	ے سے بساوے بھے جنے سے سے سے سے بھرور					
WO	9959974	Α	25-11-1999	AU	4262799 A	06-12-1999 25-11-1999
				CA WO	2332316 A1 9959974 A1	25-11-1999 25-11-1999
				WO EP	1086084 A1	28-03-2001
				ĴΡ	2002515489 T	28-05-2002
				US	6414154 B1	02-07-2002
MO	9964044	Α	16-12-1999	 AU	4335299 A	30-12-1999
110	<b>330</b> ,01.			AU	4336899 A	30-12-1999
				AU	4337699 A	30-12-1999
				AU	4423499 A	30-12-1999 30-12-1999
				AU AU	4425399 A 4426599 A	30-12-1999
				AU	4543599 A	30-12-1999
				AU	4543799 A	30-12-1999
				AU	4543999 A	30-12-1999
				AU	4549199 A	30-12-1999
				AU	763638 B2 4550899 A	31-07-2003 30-12-1999
				AU AU	4551499 A	30-12-1999
				AU	4551599 A	30-12-1999
				AU	4552099 A	30-12-1999
				AU	4557099 A	30-12-1999
				AU	4672799 A	30-12-1999
				AU AU	4674799 A 4675199 A	30-12-1999 30-12-1999
				AU	4675299 A	30-12-1999
				AU	4675399 A	30-12-1999
				AU	4675499 A	30-12-1999
				AU	4677699 A	10-01-2000
				AU	4818199 A 5203999 A	30-12-1999 30-12-1999
				AU BR	9910832 A	16-10-2001
				CA	2315883 A1	16-12-1999
				CA	2318055 A1	16-12-1999
				CA	2318192 A1	16-12-1999
				CA	2318286 A1	16-12-1999 16-12-1999
				CA CA	2318547 A1 2318894 A1	16-12-1999 16-12-1999
					7 3 1 0 0 YH H I	111-17-1777
						= =
				CA CA	2319068 A1 2319159 A1	16-12-1999 16-12-1999

#### IN LEKIM LICITAL SEARCH REPURT

Inten **Application No** imormation on patent family members PC1/US 03/39732

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9964044	A		CA	2319175 A1	16-12-1999
	•		CA	2319496 A1	16-12-1999
			CA	2319497 A1	16-12-1999
			CA	2319643 A1	16-12-1999
			CA	2319650 A1	29-12-1999
				2319651 A1	16-12-1999
			CA		16-12-1999
			CA		
			CA	2319751 A1	16-12-1999
			CA	2319756 A1	16-12-1999
			CA	2320926 A1	16-12-1999
			CA	2321120 A1	16-12-1999
			CA	2321152 A1	16-12-1999
			CA	2321170 A1	16-12-1999
			CA	2321191 A1	16-12-1999
WO 9709308	Α	13-03-1997	AU	717422 B2	23-03-2000
MO 3703300	**	10 00 100.	AU	6965096 A	27-03-1997
			BR	9606619 A	23-12-1997
			CA	2203912 A1	13-03-1997
				1173867 A	18-02-1998
			CN		12-11-1997
			CZ	9701328 A3	
			EP	0789688 A1	20-08-1997
			HU	9701714 A2	28-06-1999
			JP	10508321 T	18-08-1998
			NO	972016 A	17-06-1997
			NZ	318228 A	29-07-1999
			PL	320010 A1	01-09-1997
			TR	9700334 T1	21-08-1997
			WO	9709308 A1	13-03-1997
			US	6245761 B1	12-06-2001
WO 03087098	A	23-10-2003	BR	0210016 A	15-06-2004
MO 02001030	A	23-10-2003		2448525 A1	23-10-2003
			CA		18-08-2004
			CZ	20033202 A3	<del>_</del> -
			MO	03087098 A1	23-10-2003
			EP	1399443 A1	24-03-2004
			HU	0400017 A2	28-06-2004
			US	2004171620 A1	02-09-2004
WO 03068237	A	21-08-2003	CA	2476113 A1	21-08-2003
,	- <del>-</del>		WO	03068237 A1	21-08-2003
			US	2004014763 A1	22-01-2004
WO 03070244	Α	28-08-2003	WO	03070244 A1	28-08-2003
WO 03075853	A	18-09-2003	WO	03075853 A2	18-09-2003
	••		US	2003216434 A1	20-11-2003
WO 03028641		10-04-2003	CA	2460594 A1	10-04-2003
.,			EP	1432693 A2	30-06-2004
			MO	03028641 A2	10-04-2003
EP 1378510		07-01-2004	BR	0208167 A	09-03-2004
ri 19/0310	71	0, 01 L007	CA	2440264 A1	26-09-2002
			EP	1378510 A1	07-01-2004
				0400229 A2	30-08-2004
			UH		
			JP	3558079 B2	25-08-2004
			NO	20034148 A	14-11-2003

# mormation on patent family members

Inter Il Application No PC1/US 03/39732

					101/03	03/39/32
	tent document in search report		Publication date		Patent family member(s)	Publication date
FP	1378510	A		US	2004082584 A1	29-04-2004
	20,002	• •		CZ	20032531 A3	14-01-2004
				WO	02074770 A1	26-09-2002
				JP	2004196822 A	15-07-2004
P(U	02074770	Α	26-09-2002	BR	0208167 A	09-03-2004
WO	02074770	, ,	20 03 2002	CA	2440264 A1	26-09-2002
				CZ	20032531 A3	14-01-2004
				EP	1378510 A1	07-01-2004
				HU	0400229 A2	30-08-2004
				WO	02074770 A1	26-09-2002
				JP	3558079 B2	25-08-2004
				JP	2004196822 A	15-07-2004
				NO	20034148 A	14-11-2003
				US	2004082584 A1	29-04-2004
WO	0190106	A	29-11-2001	AT	260914 T	15-03-2004
				AU	5248201 A	03-12-2001
				BG	107140 A	30-05-2003
				BR	0110955 A	03-06-2003
				CA	2408909 A1	29-11-2001
				CN	1437599 T	20-08-2003
				CZ	20023806 A3	14-01-2004
				DE	60102233 D1	08-04-2004 07-06-2004
				DK EE	1284974 T3 200200656 A	15-06-2004
				EP	1284974 A2	26-02-2003
				ES	2215129 T3	01-10-2004
				HÜ	0302474 A2	28-11-2003
				WO	0190106 A2	29-11-2001
				JP	2003534343 T	18-11-2003
				MX	PA02011631 A	27-03-2003
				NO	20025227 A	31-10-2002
				NZ	521477 A	30-07-2004
				PL	359267 A1	23-08-2004
				PT	1284974 T	30-06-2004
				SI	1284974 T1	31-08-2004
				SK	16432002 A3	08-01-2004
				TR	200400541 T4	21-04-2004
				US	2004067977 A1	08-04-2004 31-01-2002
				US ZA	2002013337 A1 200209516 A	22-10-2003
	,					22-10-2003
WO	0218335	Α	07-03-2002	AU	8018701 A	13-03-2002
	ت سے بی ہے ہیں ہے ہے۔	ہدا جہ جہ کہ ہے ہے		WO	0218335 A1	07-03-2002
EP	1236726	Α	04-09-2002	AU	1650601 A	12-06-2001
				BR	0016111 A	25-03-2003
				CA	2394679 A1	07-06-2001
				EP	1236726 A1	04-09-2002
				HU	0300641 A2	28-06-2003 26-07-2002
				NO	20022609 A 2004097511 A1	20-05-2004
					/:::::::::::::::::::::::::::::::::::::	といっしつっていりも
				US CN		· ·
				CN	1433419 T	30-07-2003
						·
	9825897		18-06-1998	CN WO ZA	1433419 T 0140227 A1	30-07-2003 07-06-2001

imprmation on patent family members

Inter | I Application No PC1/00 03/39732

Patent document cited in search report			Patent family member(s)		Publication date
WO 9825897	Α		WO US	9825897 A1 5965565 A	18-06-1998 12-10-1999
WO 0136418	A	25-05-2001	AU WO	1382901 A 0136418 A1	30-05-2001 25-05-2001